Study of BMX-001 with paclitaxel for advanced ovarian or endometrial cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a new drug called BMX-001 combined with the chemotherapy drug paclitaxel for people with advanced ovarian or endometrial cancer that has come back or spread. The goal is to see if this combination can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced ovarian or endometrial cancer that has progressed during or after standard treatment.
- You must be at least 18 years old.
- You should be generally active and able to care for yourself (ECOG performance status 0-1).
- You must have measurable or detectable disease (like tumors or fluid buildup).
- Your kidney, liver, and blood cell counts must be within acceptable levels.
- You must have fully recovered from recent surgeries, with at least 1 week since minor surgery and 21 days since major surgery.
- You must have stopped other cancer treatments at least 28 days before starting this study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding weekly paclitaxel to an experimental drug called OK-1 can help treat advanced or recurrent endometrial cancer that has stopped responding to other treatments. It aims to see if the combination is safe and effective.
This study tests a new drug (B013) combined with a standard chemotherapy (paclitaxel) for people with ovarian cancer that has come back after platinum-based treatment. The goal is to see if the combination works better than the current options.
This study tests an experimental version of the chemotherapy drug paclitaxel for people with advanced breast cancer. It may help shrink tumors and slow the cancer's growth.
This Phase 1 trial studies BP1001-A in people with advanced or recurring solid cancers to find a safe dose and learn how the treatment works. You may be asked for tumor biopsies before and possibly after treatment to see how the cancer responds.
This trial tests a new drug called BL-B01D1 against standard chemotherapy for people with ovarian cancer that no longer responds to platinum-based treatments. The goal is to see which option works better.
This study tests a new combination treatment for people with advanced ovarian, fallopian tube, or primary peritoneal cancer that has progressed after at least two prior treatments. The aim is to see if this treatment can help shrink tumors and improve outcomes.
Hear when a new Ovarian Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.